ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Results from AD Clinicals -- But NO Biomarkers Data

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Dec 21, 2020 1:27pm

128 Views

Post# 32153618

RE:Results from AD Clinicals -- But NO Biomarkers Data

Wow, trial stared 7 Years ago and is showing promise.

At this rate, by the time PMN310 gets to trial, dementia as a whole will have been resolved.

Somethings gonna have to give in 2021 to get this thing going once and for all or the train will have passed and we'll all be still standing at the station.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market